Duke & Deerfield Announce Four Points Innovation
Duke University and Deerfield Management Company, a healthcare investment firm, announced the creation of a major translational research collaboration. The alliance is expected to accelerate the preclinical development of new drugs for improved quality of life and cures for disease.
NEW START-UP: Tellus Therapeutics
Tellus is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus’ lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in animal models of perinatal brain injury and multiple sclerosis, and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.
VielaBio Announces U.S. FDA Approval of UPLIZNA™
Viela Bio has been approved for a drug to treat adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody-positive.
17 NEW START-UPS CREATED
This year we’ve helped grow and develop ventures ranging from cancer therapeutics to digital health tools.
3D-Printing Gives Medical Teams COVID Protection
COVID-19 Engineering Response Team tackles powered, air-purifying respirator (PAPR)
November is INNOVATION MONTH
Join us in celebrating the diverse accomplishments of Duke innovators and entrepreneurs. All month long, we’ll be showing off featured technologies, inventions, and novel ideas that illustrate the breadth of Duke discoveries. We will also highlight Duke’s innovation and entrepreneurship resources, encouraging networking among Duke inventors and the broader community. #InventedAtDuke
105 AGREEMENTS
NEW START-UP: Upstream Biotechnology
Developing broad-spectrum disease-resistant crops to eliminate pesticide use, reduce production costs, and increase crop yield
NEW START-UP: Tumult Labs
Algorithm and software platform that systematically de-identifies data such that original data cannot be reconstructed